A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.
- Published
- 17 June 2019
- From
-
POZ
As the national population of patients who are HIV-positive continues to age, rheumatologists will be increasingly called on to manage routine care for crystal disease, osteoarthritis, soft tissue rheumatism and other conditions, according to Leonard Calabrese, DO, of the Cleveland Clinic.
- Published
- 22 May 2019
- From
-
Healio
Men with HIV who use testosterone have greater bone mass density (BMD) T-scores at the lumbar spine, total hip, and femoral neck compared with nonusers, according to the results of a recent study.
- Published
- 03 January 2019
- From
-
American Journal of Managed Care
In an interview with Infectious Disease Advisor, Todd T. Brown, MD, PhD, professor of medicine and epidemiology, division of endocrinology, diabetes, and metabolism, Johns Hopkins University, Baltimore, Maryland, discussed the effects of HIV infection and ART on BMD, as well as management strategies for HIV patients at risk for fragility fracture.
- Published
- 11 September 2017
- From
-
Infectious Disease Advisor
TAF containing products can be made available to patients who have defined renal or bone problems or who have medical reasons why they cannot take other HIV drugs.
- Published
- 06 March 2017
- From
-
NHS England
I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?
- Published
- 20 September 2016
- From
-
BETA blog
Results from an open-label study in young people using PrEP showed that impact on bone health might be important is daily dosing is used for many years.
- Published
- 19 September 2016
- From
-
HIV i-Base
Recent talk about HIV and aging has almost always been scary. A number of studies conclude that people living with HIV have so-called “accelerated aging”—meaning they will suffer heart attacks, strokes, cancers, and osteoporosis more often and sooner than those without HIV. Well, this is one article on aging and HIV that will challenge the concept of people living with HIV having an early expiration date. Instead, we can look at what we know and what we don’t, to get a better idea of what the risks are for HIV-positive people growing older—and what they can do about them.
- Published
- 08 July 2016
- From
-
Positively Aware
Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.
- Published
- 02 June 2016
- From
-
New York Times
More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.
- Published
- 30 May 2016
- From
-
Los Angeles Times
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...